<DOC>
	<DOCNO>NCT02974504</DOCNO>
	<brief_summary>A multi-center , randomize , double-blind , active-controlled , parallel group , phase IV clinical trial investigate effect blood glucose evogliptin oral administration patient type 2 diabetes</brief_summary>
	<brief_title>Phase IV Clinical Trial Investigate Effect Blood Glucose Evogliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description>1 . Evogliptin 5mg Group : Administration Evogliptin 5mg 0-24 week . 2 . Liniagliptin 5mg Group : Administration linagliptin 5mg 0-12 week , Evogliptin 5mg 13-24 week</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Subjects 7.0 % ≤HbA1c≤10.0 % screen Subjects untreated oral hypoglycemic agent within 8 week prior screen Subjects 20kg/m2≤BMI≤40kg/m2 screen Subjects fast plasma glucose≥270mg/dL screen Patients type 1 diabetes mellitus , secondary diabetes mellitus gestational diabetes mellitus Subjects history myocardial infarction , cerebral infarction within 24 week prior screen Subjects ALT AST 3 time high upper normal range</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>